Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
venetoclax + daunorubicin + cytarabine
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Venetoclax + daunorubicin + cytarabine is a combination regimen under investigation for the treatment of acute myeloid leukemia (AML), particularly in newly diagnosed or high-risk patients. Venetoclax is a selective B-cell lymphoma 2 (BCL-2) inhibitor that promotes apoptosis in cancer cells dependent on BCL-2 for survival. Daunorubicin is an anthracycline antibiotic that intercalates DNA, inhibits topoisomerase II, and generates free radicals leading to DNA damage and cell death. Cytarabine is an antimetabolite that inhibits DNA synthesis during the S-phase of the cell cycle by acting as a pyrimidine analog. This combination aims to enhance anti-leukemic efficacy by targeting multiple pathways involved in leukemic cell survival and proliferation[1][2][5][7]. The regimen has shown promising response rates but can be associated with significant myelosuppression.
- Brand names
- Venclexta (venetoclax)Cerubidine (daunorubicin)Cytosar-U (cytarabine)
- Other names
- Ven + DAVen/DAvenetoclax plus daunorubicin and cytarabine
02
Targets
DNA polymerase familyBCL-2 (BCL-2 family)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on venetoclax + daunorubicin + cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on venetoclax + daunorubicin + cytarabine.